Background: In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) treated with lapatinib and capecitabine (LC).
introduction
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is a disease with distinct clinicopathological features, which accounts for up to one third of all invasive breast tumors [1] . Clinically, HER2+ disease is characterized by a particularly aggressive course whose natural history, however, has been dramatically improved since the introduction of the anti-HER2 monoclonal antibody trastuzumab [2] . Interestingly, HER2 overexpression has recently emerged as a clear risk factor for the development of brain metastases (BMs) [3, 4] , and trastuzumab treatment, despite its positive effect on overall prognosis, appears to substantially contribute to this risk [5] [6] [7] . In fact, trastuzumab does not fully cross the blood-brain barrier (BBB) [8, 9] , thus making the brain a 'sanctuary' site for the development of metastases. In addition, several retrospective analyses of HER2+ metastatic BC patients treated with trastuzumab-based therapies showed that about one third of these patients develop BMs [6, 7, [10] [11] [12] [13] [14] , and in more than half of these cases BMs occur in patients with either responsive or stable disease at extracranial sites. These results support the hypothesis that trastuzumab has limited ability to penetrate the BBB and highlight the importance of developing novel systemic strategies beyond local standard approaches of cranial radiotherapy to more effectively prevent or treat BMs from HER2+ BC.
Lapatinib is a small molecule, dual HER1/HER2 inhibitor with a theoretical ability to cross the BBB. Preclinical evidence supports the activity of lapatinib against cerebral nervous system (CNS) disease [15] , which could explain, in an unplanned exploratory analysis of the phase III study of lapatinib plus capecitabine (LC) versus capecitabine alone, the fewer CNS relapses as site of first progression associated with combination therapy (25% versus 6%, respectively; P = 0.045) [16] . For patients with established CNS metastases, two phase II studies investigated the activity of lapatinib monotherapy in HER2+ BC pretreated with trastuzumab who had developed BMs and had progressed after cranial radiation. These studies reported a modest activity of lapatinib monotherapy but original article showed a volumetric reduction in brain burden in additional patients in exploratory analyses [17, 18] . In the second international phase II trial, a cohort of 50 patients whose CNS disease had progressed on lapatinib monotherapy entered an extension phase involving treatment with both LC obtaining an overall response rate in the brain of 20% [18] . In the present analysis, the clinical outcome of patients with BMs from HER2+ BC treated with LC was evaluated and it was compared with that of a cohort of patients treated with trastuzumab-based therapies only beyond brain progression. Response of BMs, the brain-specific progression-free survival (BPFS) and the overall survival (OS) (from the start of LC) of these 30 patients treated with LC were evaluated. Patients were considered evaluable for response of BMs: (i) in the presence of progressive BMs, (ii) in the presence of one or more measurable BMs ‡1 cm in diameter, (iii) in case of prior neurosurgery residual disease had to be documented radiologically, (iv) if cranial radiotherapy (whole brain radiation therapy and/or stereotactic radiosurgery) had been completed ‡2 months before the start of LC.
In a second step, the OS from the time of development of BMs of patients treated with LC was compared with the OS of 23 patients who were treated consecutively with trastuzumabbased therapies only beyond brain progression at our institutions in the pre-lapatinib era [13, 14] .
statistical analysis
Response of BMs to LC was evaluated according to the World Health Organization (WHO) criteria [19] . Response of BMs was evaluated every 3 months by using the same radiological method of assessment as baseline. Duration of response in the brain was calculated from the first documented response until brain progression or death in the absence of brain progression. Progression-free survival (PFS) was the time elapsed from the date of initiation of LC to the date of first evidence of disease progression or death in the absence of disease progression. The BPFS was defined as the time from the start of LC to the date of documented brain progression or death in the absence of disease progression in the brain. The OS time was measured from the start of LC (OS1) and from the time of development of BMs (OS2) to the date of death for any cause. In the absence of brain progression or death, BPFS, OS1 and OS2 were censored at the time of the last visit. Time to event (BPFS, OS1 and OS2) was analyzed according to Kaplan-Meier method and survival curves were compared using the log-rank test. Given the retrospective nature of the study, statistical significance should be used in an exploratory view and median time estimation with their 95% confidence interval (CI) reported to better interpret the data. SPSS software version 17.0 was used for statistical analyses (SPSS Inc., Chicago, IL). The median follow-up time from the initiation of LC was 9 months (range 2-31). The median duration of treatment with LC was 4 months (range 2-25). Twenty-two patients were evaluable for response in the brain: 7 partial responses (31.8%) and 6 disease stabilizations (27.3%) were observed ( Table 2) . 
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BMs, brain metastases; SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy. The median duration of brain response was 6 months (range 3-25): it was 18 months (range 7-25) in the three patients who had not received any prior local treatment for BMs, while it was 4.5 months (range 3-6) in the four patients who had received prior local therapy. At 6 months, 57% of responsive patients were alive and free from brain progression compared with 27% of patients with stable or progressive BMs (P = 0.02). At 1 year, 67% of responsive patients were alive compared with 33% of patients with stable or progressive BMs (P = 0.02).
Response of BMs was related to the local treatment delivered prior to LC (Table 2) : three responses (75%) and one disease stabilization (25%) in the brain were observed in the four patients who did not receive any local treatment for BMs. The three responding patients had £3 brain lesions and received LC as first systemic option after the development of BMs. At the time of the analysis, two of these three patients had not yet experienced disease progression, with confirmed brain responses after 5 and 21 months of treatment, respectively. The third patient discontinued LC after 14 months of treatment due to extracranial only progression of disease ( Figure 1 ).
All 30 patients were considered for the analysis of PFS, BPFS and OS from the start of LC (OS1): the median PFS was 5.1 months (95% CI 2.6-7.5) and the median BPFS was 5.6 months (95% CI 4.4-6.8) (Figure 2A ). At the time of this analysis, 5 of 30 patients had not yet experienced either intra-or extracranial disease progression and are still receiving LC. In the remaining 25 patients, treatment was discontinued due to disease progression: 4 patients for extracranial-only disease progression and 21 patients for disease progression both at intra-and extracranial sites. Eighteen patients have died and the median OS from the start of LC (OS1) was 11 months (95% CI 4.3-17.6) ( Figure 2B ). Treatments after LC in the 25 progressive patients were trastuzumab-based in 11 patients, chemotherapy without trastuzumab in 9 patients and symptomatic therapy only in 5 patients. Figure 3A) . Median OS2 was not reached in the 6 patients who received LC as first systemic option after the development of BMs, while it was 27.1 months in the 24 patients who received LC after at least one trastuzumab-based therapy following the development of BMs ( Figure 3B) . Two-year OS2 was 66% for responsive patients compared with 44% for patients with stable or progressive BMs (P = 0.11).
Median OS2 of the 30 patients treated with LC was then compared with the median OS2 of 23 patients who received only trastuzumab-based therapies beyond brain progression [13, 14] . The characteristics of these 23 patients were similar to those of the LC group (Table 3) . In patients treated with LC, median OS2 was significantly higher than that of patients treated only with trastuzumab-based therapies beyond brain progression (27.9 months versus 16.7 months, respectively, P = 0.01) ( Figure 3A) . discussion Due to their high incidence, BMs represent an important cause of morbidity and mortality in HER2+ metastatic BC patients. In our retrospective analysis, patients naïve for both lapatinib and capecitabine reported a 31.8% of response rate in BMs according to WHO criteria. As single agents, lapatinib and capecitabine have shown to be active for BMs in patients with HER2+ disease [17, 18] or unselected for HER2 status, respectively [20, 21] . More in detail, an international phase II study, which enrolled 242 patients pretreated with trastuzumab and with progressive BMs after radiotherapy, showed only a 6% response rate in the brain (defined by composite criteria) for single-agent lapatinib, but a 20% response rate in the brain was observed in additional patients with radiographically documented CNS progression who had entered the LC extension phase of the study [18] . For this reason, it is likely that the LC combination might act synergistically against BMs. This hypothesis has been confirmed by the results reported in the LC expanded access programs: 18% of responses in the brain were reported by Boccardo et al. [22] and 21% of responses were observed by Sutherland et al. [23] , despite the fact that prior capecitabine had been administered in 42% and 35% of patients, respectively.
Interestingly, previous treatment with capecitabine reduced the objective response rate in the brain: in the Sutherland study, the rate of brain response was lower in patients previously treated with capecitabine (16.7%) compared with the capecitabine-naïve group (30%) (P = 0.2) [23] . These results are close to the 31.8% of responses obtained in our analysis, which was conducted in a similarly naïve population for both lapatinib and capecitabine. Nevertheless, this comparison is limited by the different criteria used for CNS response assessment (RECIST in the Sutherland study versus WHO in our experience). However, at the present time, there are no standard neurooncology criteria to evaluate response in BMs. To this regard, Lin et al. [18] employed a CNS composite response criteria where CNS objective response was defined as ‡50% volumetric reduction of CNS in the absence of increasing steroid use, progressive neurological signs and symptoms or progressive extra-CNS disease.
Remarkably, we observed three partial responses with LC in four patients who had not received any local treatment for BMs (Figure 1 ). This finding might suggest that systemic treatment with LC is active on BMs in patients who have not been previously treated with cranial radiotherapy.
Continuation of anti-HER2 treatments in patients progressing during trastuzumab-based therapies is associated with improved clinical outcome in patients with HER2+ metastatic BC [16, [24] [25] [26] . Similarly, continuation of trastuzumab-based therapies beyond brain progression has been associated with an improvement in survival [13, 14, 27, 28] , which appears to be mainly function of an increased control of extracranial disease [13, 14] . In a recent retrospective analysis, treatment with lapatinib after the development of BMs 
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was one of the factors associated with prolonged survival from the diagnosis of BMs [7] . In our study, we reported a significantly longer OS from the development of BMs (OS2) for patients who had also received LC compared with a similar population treated only with trastuzumab-based therapies beyond brain progression (27.9 months versus 16.7 months; P = 0.01; Figure 3A ). This highlights the potential impact of an additional anti-HER2 therapy with LC in patients with CNS progression on prior trastuzumab. Furthermore, the observation that the 2-year OS2 was higher in patients with responding BMs compared with those with stable or progressive CNS disease (66% versus 44%) provides evidence that the achievement of brain response is important for further improving the outcome of patients with BMs from HER2+ BC. Finally, the fact that patients who received LC as first systemic option after the development of BMs derived the greatest benefit from treatment ( Figure 3B ) might suggest that patients who develop BMs during trastuzumab-based therapies should undergo early initiation of LC in order to derive the greatest benefit from treatment.
In conclusion, this retrospective analysis shows that LC is an active combination against BMs from HER2+ BC in patients naïve for both lapatinib and capecitabine. Treatment with lapatinib and capecitabine after the development of BMs may further improve the prognosis of patients with BMs from HER2+ BC compared with the exclusive use of trastuzumabbased therapies beyond brain progression. This positive effect on survival can be at least in part attributed to the higher activity of LC on BMs compared with trastuzumab-based therapies beyond brain progression. Further evaluation of systemic strategies including LC in HER2+ BC patients with BMs is advocated.
